This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401Phase 3Recruiting
- Lead sponsor
- Pfizer (Industry)
- Enrollment
- 714 (estimated)
- Start date
- 23 Jul 2025
- Primary completion
- 5 Sep 2028 (estimated)
- Study completion
- 1 Mar 2029
- Last update posted
- 25 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Single
- Arms
- 2
Interventions
- Sigvotatug Vedotin Drug
- Pembrolizumab Drug
Conditions and primary outcome
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non-Small-Cell Lung (NSCLC)
Primary outcome
Overall Survival (Baseline to date of death from any cause (Approximately 2 years).); Progression Free Survival (PFS) assessed by blinded independent central review (BICR) (From Baseline to to date of first documentation of progression OR death (Approximately 2 years).)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedFrontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design.
Future oncology (London, England) · 2025 Dec
PubMed 41388832 (opens in a new tab)DOI 10.1080/14796694.2025.2596228 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06758401 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.